Many hopes for an effective coronavirus treatment are being pinned on chloroquine, not least those of President Trump, and pharma companies are supplying the antimalarial to the US at no cost for use in clinical trials.
There is no proof yet that chloroquine is effective in treating COVID-19 but the antimalarial discovered by Bayer AG in 1934 has quickly become the great hope for tackling the symptoms of the coronavirus.
The decades-old drug went back under the spotlight following a rambling press conference from Donald Trump as the US president...
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
